Headline News

SAN ANTONIO — A swallowable hydrogel capsule that expands in the stomach demonstrated significant weight-loss, cardiovascular, glycemic and quality of life benefits for patients with overweight or obesity, a speaker reported.

BARCELONA, Spain – In this Healio Video Perspective from the Euretina congress, Tien Yin Wong, MD, shares his thoughts on the emerging role of AI in retina.

BOSTON — Physicians should be prepared to bust some myths during discussions with families about food allergy testing, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

INDIANAPOLIS — According to the National Keratoconus Foundation, Nov. 10 is World Keratoconus Day, which is dedicated to raising awareness about the condition and advocating for those affected by it.

SAN ANTONIO — In this Healio video exclusive from ObesityWeek, Fatima Cody Stanford, MD, MPH, MPA, MBA, MACP, FAAP, FAHA, FTOS, discusses equitable access to obesity care and treatments in the U.S.

The FDA has extended the target action date of its review of the supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged at least 2 years, Organon announced in a press release.

Current adult smokers with access to a digital pet game within a smoking cessation app had better app engagement and program adherence vs. those without game access, according to results published in Journal of Medical Internet Research.

From birth to 24 years, individuals who ended up with high or low BMIs had reduced lung function, whereas those who ended up with a normal range BMI did not have this outcome, according to results published in European Respiratory Journal.

PHILADELPHIA — Rebyota was safe and effective at 8 weeks and up to 6 months in patients with recurrent Clostridioides difficile infection, many of whom had other gastrointestinal comorbidities and risk factors, according to data presented.

Healio spoke with John Molina, MD, MEd, about research on the use of minimal residual disease testing in acute lymphoblastic leukemia presented at Society of Hematologic Oncology Annual Meeting.